Lv7
4970 积分 2024-03-07 加入
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
5小时前
待确认
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
9天前
已完结
Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy
12天前
已完结
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
14天前
已完结
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
19天前
已完结
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck
21天前
已完结
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
23天前
已完结
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
23天前
已完结
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer
29天前
已完结
Association between gout and polymorphisms in GCKR in male Han Chinese
1个月前
已完结
皖公网安备34019202002308
